Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
The analysis of the financial ratios over the observed quarters reveals several noteworthy trends in the company's leverage and ability to cover interest expenses.
- Debt to Equity
- The debt to equity ratio demonstrates a general declining trend from 0.50 in April 2021 to around 0.33 by September 2025. Although there are minor fluctuations, notably a slight increase in September 2023, the overall pattern indicates a reduction in reliance on equity financing relative to debt.
- Debt to Capital
- This ratio also shows a decreasing trend over the period, moving from 0.33 in April 2021 to approximately 0.25 by the end of the horizon. The decline suggests a gradual shift towards a lower proportion of debt in the total capital structure, with some minor volatility but no significant reversals.
- Debt to Assets
- The debt to assets ratio follows a similar downward trend, declining from 0.27 in April 2021 to around 0.21 in subsequent quarters. This pattern reflects a moderate decrease in the proportion of assets financed through debt, improving the company’s asset financing quality.
- Financial Leverage
- Financial leverage, defined as total assets divided by equity, decreases steadily from about 1.87 at the start of the period to approximately 1.56 by the last quarter analyzed. This trend confirms a gradual reduction in the degree to which the company is levered, suggesting a conservative approach to capital structure over time.
- Interest Coverage
- Interest coverage, representing the ability to meet interest obligations from earnings, exhibits a different pattern. It initially improves significantly, rising from 21.54 in April 2021 to a peak of 41.32 in September 2022. After this peak, the ratio declines consistently to around 15-17 range by late 2024 and 2025. This decrease, while still showing adequate coverage, indicates reduced earnings relative to interest expense over time.
In summary, the company shows a strategic reduction in leverage across several dimensions, improving the stability and quality of its capital structure. However, the decline in interest coverage after a strong peak suggests some pressures on earnings relative to interest expenses in the latter periods, which may warrant further monitoring.
Debt Ratios
Coverage Ratios
Debt to Equity
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Debt to equity = Total debt ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data over multiple quarters indicates evolving trends in the company's capital structure, specifically focusing on total debt, stockholders' equity, and the debt-to-equity ratio.
- Total Debt
- Total debt initially fluctuated, rising from approximately $20.3 billion in early April 2021 to a peak near $23.6 billion by October 2021. Following this peak, there is a general downward trend with minor variations, declining to about $16.0 billion by December 2024. Some quarters show slight increases, such as in late 2023, but overall leverage has decreased over the observed period.
- Total Stockholders’ Equity
- Stockholders' equity displayed steady growth from $40.4 billion in April 2021, rising consistently to reach over $53.4 billion by late 2023. Thereafter, equity experiences some volatility, dipping to roughly $49.6 billion by June 2024 before recovering somewhat towards the end of the period, ending near $51.1 billion in September 2025. This reflects ongoing accumulation of equity, though with some fluctuations in the final phase.
- Debt to Equity Ratio
- The debt-to-equity ratio demonstrates a gradual decline through the timeline, starting from 0.50 in April 2021 and falling to as low as 0.32 by mid-2024 and continuing at this reduced level through 2025. This declining ratio indicates an improving balance sheet with relatively lower debt compared to equity, suggesting either active debt reduction, equity growth, or both.
In summary, the company shows an overall strengthening of its financial position by reducing leverage over time. The consistent increase in equity coupled with a decline in total debt contributes to an improving debt-to-equity ratio, reflecting a shift towards a more conservative capital structure. While some short-term variations are present, the long-term trend suggests disciplined financial management aimed at reducing risk and enhancing shareholder value.
Debt to Capital
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt exhibited some fluctuations over the observed quarterly periods. Initially, debt rose from approximately $20.3 billion to nearly $23.6 billion in late 2021, indicating increased leverage during this phase. Subsequently, from early 2022 onwards, the debt trend generally declined, reaching a low near $16.0 billion by the end of 2024. Minor increases and decreases occurred intermittently, with a notable rise around Q3 2023 before declining again towards mid-2025. Overall, the latter part of the period reflects a consolidation and reduction in leverage relative to earlier quarters.
- Total Capital
- Total capital showed a steady upward trend from about $60.7 billion in Q2 2021 to a peak near $74.5 billion in late 2023. Following this peak, the total capital decreased somewhat, falling back to approximately $67.9 billion by Q3 2025. This pattern suggests capital expansion in the earlier quarters, potentially driven by equity growth or retained earnings, followed by a retraction or capital optimization in the latter periods.
- Debt to Capital Ratio
- The debt to capital ratio demonstrated a gradual improvement over the timeline, decreasing from a high of 0.35 in late 2021 to around 0.25 by mid-2025. This decline indicates a strategic reduction in the proportion of debt relative to the company’s capital base, which may reflect deleveraging efforts and a stronger capital structure. The ratio remained relatively stable around 0.25 in the most recent quarters, suggesting a consistent approach to maintaining financial leverage at a conservative level.
- Overall Analysis
- The data reveal a period of increased borrowing through 2021 followed by disciplined debt reduction and capital management in subsequent years. The increasing total capital until late 2023 combined with declining debt to capital ratio points to enhanced financial stability and potentially improved credit metrics. The slight decrease in total capital after late 2023 suggests a possible shift in capital allocation or distribution policies. The stabilization of the debt to capital ratio near 0.25 reflects a balanced approach to financial leverage, supporting sustainable operations and possibly improved investor confidence.
Debt to Assets
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Notes payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends regarding the company’s debt and asset management over the quarters presented.
- Total Debt
- Total debt initially increased from approximately $20.3 billion to $23.6 billion in late 2021, then gradually declined to about $16.0 billion by mid-2024. Following this low point, debt levels fluctuated moderately, ending near $16.9 billion by late 2025. This trend suggests a period of initial debt accumulation followed by a sustained deleveraging phase, with some variability in recent quarters.
- Total Assets
- Total assets generally exhibited growth from around $75.4 billion in early 2021, peaking near $87.7 billion by late 2023. Subsequently, assets declined to approximately $77.5 billion by mid-2024 but recovered somewhat thereafter, ending close to $79.9 billion in late 2025. This pattern indicates an overall expansion of asset base with some volatility during the mid-term period.
- Debt to Assets Ratio
- The debt to assets ratio showed a gradual decrease over time, moving from roughly 0.27 in early 2021 down to approximately 0.21 by late 2025. This decline reflects improved leverage management, as the company reduced its relative debt burden compared to the size of its asset base. The ratio stabilized around 0.21 towards the end of the period, indicating a consistent capital structure.
In summary, the data demonstrates a cautious approach to debt, with a notable reduction in total debt levels and an increasingly conservative leverage ratio. The company’s asset base expanded over the period, though with some fluctuations, contributing to enhanced financial stability as indicated by the lower debt to asset ratio.
Financial Leverage
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Financial leverage = Total assets ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total Assets
-
Total assets exhibited a general pattern of growth from April 2021 through the first quarter of 2023, increasing from approximately 75.4 billion USD to a peak near 87.7 billion USD in the third quarter of 2023. Following this peak, total assets showed some volatility with a downward trend overall, decreasing to roughly 79.9 billion USD by the third quarter of 2025.
This suggests a phase of asset expansion for approximately two years followed by a moderate contraction or asset optimization strategy over the subsequent period.
- Total Danaher Stockholders’ Equity
-
Stockholders’ equity rose steadily from about 40.4 billion USD in early 2021 to a high near 53.5 billion USD by the end of 2023. After this peak, equity levels declined somewhat to around 51.1 billion USD by the third quarter of 2025.
The increase in equity over the initial years indicates value creation or retained earnings accumulation, while the later decrease may point to share repurchases, dividend payments, or other equity adjustments.
- Financial Leverage
-
The financial leverage ratio demonstrated a consistent decrease over the entire time frame, moving from 1.87 in April 2021 to about 1.56 by the third quarter of 2025. This decline reflects a steady reduction in the use of debt relative to equity.
The trend toward lower leverage indicates a strategic shift toward a more conservative capital structure with a comparatively higher reliance on equity financing or debt repayment, potentially reducing financial risk.
Interest Coverage
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||||
| Less: Earnings from discontinued operations, net of income taxes | |||||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Interest coverage
= (EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024)
÷ (Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Earnings before interest and tax (EBIT)
- The EBIT figures demonstrate a notable volatility over the observed periods. Initially, values ranged around the 2100 million USD mark, with a sharp decline observed in the third quarter of 2021 down to 1449 million USD. This was followed by a recovery to over 2200 million USD by the end of 2022. However, starting from the first quarter of 2023, a general downward trend is noticeable, with EBIT decreasing significantly, reaching a low point around the third quarter of 2025. Occasional short-term upswings occur, but overall, the trend from 2023 onward suggests declining operating profitability.
- Interest expense
- Interest expenses have fluctuated within a moderate range, generally between 40 and 87 million USD. Initial quarters showed a slight downward movement from 58-62 million USD levels to the low 40s in late 2022, then a sharp increase to mid-80s during the first quarter of 2023. Subsequently, the expense stabilizes but remains elevated relative to earlier periods, oscillating mostly between 60 and 70 million USD towards the later quarters. The increase in interest costs could be indicative of higher borrowing or changes in interest rates affecting the cost of debt.
- Interest coverage ratio
- The interest coverage ratio exhibits a generally declining pattern over time. Starting from very high levels exceeding 20 and peaking above 40 around late 2022, the ratio steadily declines through the subsequent quarters. By mid to late 2025, coverage ratios drop below 20, reaching values around 15-16. This downward trend suggests weakening ability to service interest obligations from operating income, likely influenced by the simultaneous decrease in EBIT and relative stability or slight increase in interest expenses. The decline signals a reduction in the margin of safety for debt servicing.
- Summary
- The data reflects a period of initial robustness followed by increasing financial pressure. Operating earnings experienced volatility with a recovery phase ending in late 2022, transitioning into a gradual decline through 2025. Interest expenses rose intermittently, exerting upward pressure on financing costs. Consequently, the interest coverage ratio diminished significantly, pointing to reduced earnings cushion against interest payments. This financial pattern may warrant a closer examination of operational efficiency, debt management, and interest rate exposure to improve profitability and maintain solvency.